FDA is being more proactive about issuing safety warnings. But, as GSK's experience with Advair shows, what looks like bad news to Wall Street may not matter as much to physicians. FDA is well aware of the limitations of its risk communication techniques, but for now the agency is commited to transparency.
By Michael McCaughan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
